BioNTech Responsible Person
BioNTech SE · BioNTech US Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
57
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in non-small cell lung cancer
0
PubMed author-name match
Trials
Studies that name BioNTech Responsible Person as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:29 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07893054 · A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational DrugsBioNTech SE · not yet recruiting · Advanced Solid Tumors · study director
- Ph1/Ph2NCT07886684 · A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-TnBioNTech SE · not yet recruiting · Advanced Solid Tumors · study director
- Ph1NCT07698600 · A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVBioNTech SE · recruiting · HIV -1 Infection · study director
- Ph1/Ph2NCT07455734 · Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid TumorsBioNTech SE · recruiting · Advanced Solid Tumor Cancer · study director
- Ph2NCT07379580 · A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaBioNTech SE · recruiting · Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection · study director
- Ph3NCT07365995 · A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerBioNTech SE · recruiting · Metastatic Castration-resistant Prostate Cancer · study director
- Ph2NCT07297212 · A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent GlioblastomaBioNTech SE · recruiting · Recurrent Glioblastoma · study director
- Ph2NCT07255404 · A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic CancerBioNTech SE · recruiting · Pancreatic Ductal Adenocarcinoma (PDAC) · study director
- Ph3NCT07173751 · ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerBioNTech SE · recruiting · Breast Neoplasms · study director
- Ph1/Ph2NCT07147348 · A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid TumorsBioNTech SE · recruiting · Advanced Solid Tumor · study director
- Ph1/Ph2NCT07111520 · A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)BioNTech SE · recruiting · Non-small Cell Lung Cancer · study director
- Ph1/Ph2NCT07079631 · A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerBioNTech SE · recruiting · Metastatic Colorectal Cancer · study director
- Ph1/Ph2NCT07070232 · A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsBioNTech SE · recruiting · Advanced Solid Tumor · study director
- Ph2NCT06940804 · A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From SpermBioNTech SE · withdrawn · Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor · study director
- Ph1/Ph2NCT06892548 · A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerBioNTech SE · recruiting · Advanced Lung Cancer · study director
- Ph2NCT06841055 · Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line TreatmentBioNTech SE · recruiting · Non-small Cell Lung Cancer · study director
- Ph1/Ph2NCT06827236 · A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerBioNTech SE · recruiting · Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer · study director
- Ph1/Ph2NCT06750185 · Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsBioNTech SE · recruiting · Advanced Solid Tumor · study director
- Ph2/Ph3NCT06712316 · Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)BioNTech SE · recruiting · Non-small Cell Lung Cancer · study director
- Ph3NCT06712355 · Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerBioNTech SE · recruiting · Extensive-stage Small-cell Lung Cancer · study director
- Ph1NCT06469164 · A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial VaginosisBioNTech SE · completed · Bacterial Vaginosis · study director
- Ph2NCT06449222 · Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyBioNTech SE · active not recruiting · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers · study director
- Ph2NCT06449209 · Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyBioNTech SE · active not recruiting · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer · study director
- Ph3NCT06340568 · A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerBioNTech SE · recruiting · Endometrial Cancer · study director
- Ph1NCT06150183 · Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid TumorsBioNTech SE · active not recruiting · Advanced Malignant Solid Tumor · study director
- Ph1/Ph2NCT06069544 · A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaBioNTech SE · completed · Malaria · study director
- Ph1/Ph2NCT06069778 · Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic AdenocarcinomaBioNTech SE · terminated · Pancreatic Cancer · study director
- Ph1/Ph2NCT05988203 · A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox VaccinesBioNTech SE · completed · Monkeypox · study director
- Ph1NCT05581641 · Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaBioNTech SE · completed · Malaria · study director
- Ph1/Ph2NCT05547464 · Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated VolunteersBioNTech SE · active not recruiting · Tuberculosis · study director
- Ph1NCT05541861 · Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy PeopleBioNTech SE · completed · SARS-CoV-2 Infection, COVID-19 · study director
- Ph1NCT05537038 · Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy VolunteersBioNTech SE · completed · Tuberculosis · study director
- Ph1NCT05432583 · A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes LesionsBioNTech SE · active not recruiting · Genital Herpes Simplex Type 2 · study director
- Ph1/Ph2NCT05262530 · Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid TumorsBioNTech SE · terminated · Solid Tumor · study director
- Ph1NCT05142189 · Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerBioNTech SE · recruiting · Non-Small Cell Lung Cancer · study director
- Ph2NCT05004181 · Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy ParticipantsBioNTech SE · completed · SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease · study director
- Ph2NCT04949490 · A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial SubjectsBioNTech SE · completed · COVID-19, SARS-CoV-2 Infection · study director
- N/ANCT04813627 · Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant ChemotherapyBioNTech SE · completed · Colorectal Cancer Stage II, Colorectal Cancer Stage III · study director
- Ph1NCT04710043 · Dose Escalation Trial of BNT152+153 in Patients With CancerBioNTech SE · completed · Solid Tumor · study director
- Ph1/Ph2NCT04683939 · Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsBioNTech SE · terminated · Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma · study director
- Ph2NCT04649021 · Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationBioNTech SE · completed · SARS-CoV-2 · study director
- Ph1NCT04625205 · A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced MelanomaBioNTech US Inc. · terminated · Unresectable Melanoma, Metastatic Melanoma · study director
- Ph1/Ph2NCT04537949 · A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy AdultsBioNTech SE · completed · Covid-19, Protection Against COVID-19 · study director
- Ph2/Ph3NCT04534205 · A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1BioNTech SE · active not recruiting · Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer · study director
- Ph2NCT04526899 · A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentBioNTech SE · completed · Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma · study director
- Ph1NCT04523571 · Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy SubjectsBioNTech SE · completed · SARS-CoV-2 · study director
- Ph1NCT04503278 · A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ TumorsBioNTech Cell & Gene Therapies GmbH · active not recruiting · Solid Tumor · study director
- Ph2NCT04486378 · A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerBioNTech SE · active not recruiting · Colorectal Cancer Stage II, Colorectal Cancer Stage III · study director
- Ph1/Ph2NCT04455620 · BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid TumorsBioNTech SE · terminated · Solid Tumor · study director
- Ph1/Ph2NCT04382898 · PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)BioNTech SE · terminated · Prostate Cancer · study director
- Ph1/Ph2NCT04380701 · A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised AdultsBioNTech SE · completed · Infections, Respiratory, Virus Diseases, Infection Viral · study director
- Ph1/Ph2NCT04101357 · Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411BioNTech SE · terminated · Solid Tumor, Extensive-stage Small Cell Lung Cancer · study director
- Ph1NCT03118349 · Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as RadioimmunotherapyBioNTech Research & Development, Inc. · terminated · Pancreatic Carcinoma, Tumors That Express CA 19-9 · study director
- Ph1NCT02687230 · Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1BioNTech Research & Development, Inc. · terminated · Pancreatic Carcinoma, Tumors That Express CA19-9 · study director
- Ph1NCT02672917 · Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive MalignanciesBioNTech Research & Development, Inc. · terminated · Pancreatic Cancer · study director
- Ph1NCT02410733 · Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced MelanomaBioNTech SE · completed · Melanoma · study director
- Ph1NCT02316457 · RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uIDBioNTech SE · completed · Breast Cancer (Triple Negative Breast Cancer (TNBC)) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.